Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Patient Perspectives on the Value of Stereotactic Body Radiotherapy in the Management of Breast Cancer: The PERSPECTIVE Study.
Clin Oncol (R Coll Radiol)
December 2024
Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.
Aims: Oligometastatic disease describes limited metastases amenable to therapy such as stereotactic body radiotherapy (SBRT). This study aims to understand which outcomes are most important to patients when considering SBRT as a treatment option. The insights gained will help inform future patient-directed trial endpoints and provide valuable guidance to clinicians supporting patients through their decision-making process.
View Article and Find Full Text PDFAssociation of Socio-Environmental Burden and Inequality With Cancer Screening and Mortality.
J Surg Oncol
December 2024
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.
Background And Objectives: Social and environmental injustice may influence accessibility and utilization of health resources, affecting outcomes of patients with cancer. We sought to assess the impact of socio-environmental inequalities on cancer screening and mortality rates for breast, colon, and cervical cancer.
Methods: Data on cancer screening and environmental justice index social and environmental ranking (SER) was extracted from the CDC PLACES and ATSDR, respectively.
Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients.
Breast Cancer (Dove Med Press)
November 2024
Anhui University of Science and Technology, Huainan, Anhui, People's Republic of China.
Article Synopsis
- HER2-positive breast cancer is a high-risk subtype that sometimes requires additional treatments beyond dual-targeted therapy, and pyrrolitinib has shown promise as a potential option.
- A study involving 28 patients in China showed that adding pyrrolitinib to existing treatment resulted in significant reduction of breast cancer masses and no serious adverse reactions.
- The conclusion indicates that pyrrolitinib can be a safe and effective option for treating HER2-positive breast cancer, but further research is needed to confirm these findings.
Risk of cancer development associated with disease-modifying therapies for multiple sclerosis: study protocol for a systematic review and meta-analysis of randomised and non-randomised studies.
Syst Rev
October 2024
Centre for Biomedical Research in Mental Health Network (CIBERSAM), Institute of Health Carlos III, Madrid, Spain.
Background: The association between cancer and multiple sclerosis has long been investigated. Several studies and reviews have examined the risk of cancer among patients with multiple sclerosis treated with disease-modifying therapies (DMTs) but with conflicting results. This study will aim to investigate the association between DMTs for multiple sclerosis and subsequent cancer risk using research synthesis methods.
View Article and Find Full Text PDFArtificial Intelligence Algorithm for Subclinical Breast Cancer Detection.
JAMA Netw Open
October 2024
Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Importance: Early breast cancer detection is associated with lower morbidity and mortality.
Objective: To examine whether a commercial artificial intelligence (AI) algorithm for breast cancer detection could estimate the development of future cancer.
Design, Setting, And Participants: This retrospective cohort study of 116 495 women aged 50 to 69 years with no prior history of breast cancer before they underwent at least 3 consecutive biennial screening examinations used scores from an AI algorithm (INSIGHT MMG, version 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!